Owlstone Medical Joins 3TR To Provide Breath Biopsy Infrastructure And Analysis For Multiple Studies

Pixabay License | Source: João Hoyler Correia , no changes made.
Advertisement

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine has joined 3TR, a large-scale public-private research initiative that aims to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases. Owlstone Medical will receive funds from the project to provide Breath Biopsy Collection Stations and Kits for the collection of breath samples, and analysis services for multiple studies that have been identified at this stage as suitable to include breath sampling, alongside clinical and physiological evaluation and blood analysis.

Founded in 2004, based in Cambridge, UK, Owlstone Medical’s vision is to save 100,000 lives and $1.5 billion in healthcare costs by realising the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®. The Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, UK, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.

The new 3TR project funded by IMI2 – a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) unites renowned, interdisciplinary experts from 69 academic and industrial partner institutions, including multiple top-ten pharma, covering 15 European countries. Under the initiative, 3TR will have access to an unprecedented quantity of clinical data and samples of more than 50,000 patients across 50 ongoing and new clinical trials, ultimately aiming to discover and verify stratification biomarkers to improve patient management.

Autoimmune, inflammatory and allergic diseases are common chronic diseases that significantly affect the wellbeing of millions of people around the globe and pose a substantial burden to healthcare systems. While different treatments are available, response and disease progression in individual patients remain unpredictable, which can hamper the management of their disease.

In a never-before-seen effort to bring together experts from different medical fields, profiling technologies, systems biology and bioinformatics with specialists from innovative SMEs and leading pharmaceutical companies, 3TR – operating under the IMI2 umbrella – sets out to fundamentally increase knowledge of the molecular pathways and mechanisms linked to response and non-response to a range of therapies.

The work falls within and across seven different immune-mediated, allergic and inflammatory diseases – systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (including ulcerative colitis and Crohn’s disease), asthma and COPD. Despite their heterogeneity, recent studies have shown that on the molecular level certain patterns are shared by patients across these diseases, thus suggesting they may also share pathways of response to treatment and disease progression.

Breath sampling is expected to be deployed initially into multiple academic-led trials for asthma and COPD, however the potential exists for Breath Biopsy to extend into additional studies in other investigational areas as the 3TR initiative proceeds. Owlstone Medical will have full access to the data generated, and the rights to develop biomarkers discovered into clinical tests.

“For the first time, the 3TR team will align and integrate the analysis of autoimmune, allergic, and inflammatory conditions to identify the relationship between longitudinal molecular and microbiome profiles in blood cells and tissues, and disease paths. In a unique approach we will study the seven diseases both in parallel and jointly.” … “We believe that this high-resolution multi-omics profiling analysis of individualized response to treatment and disease progression will facilitate stratification and identification of molecular patterns that better predict response or non-response to therapy. This comprehensive approach will help identify biomarkers to improve patient management within these diseases.” – Marta Alarcón-Riquelme, scientific coordinator of 3TR and Head of Medical Genomics at the GENYO centre at the Fundación Pública Andaluza Progreso y Salud

“Currently, too little is known about the molecular basis underpinning autoimmune, inflammatory, and allergic diseases. A deeper understanding of the cellular mechanisms driving disease development is urgently needed, which will support the discovery of novel biomarkers, on breath or other sample types that can be deployed to detect disease earlier and to drive improved patient outcomes. 3TR’s ground-breaking approach to addressing this problem through integrated cross-disease analysis, led by leading academic, pharmaceutical, and other organizations, is one that Owlstone Medical is excited to be making a unique contribution to.” – Billy Boyle, co-founder and CEO at Owlstone Medical

Sources

  1. https://onenucleus.com/owlstone-medical-contribute-breath-biopsy-3tr-largest-ever-imi2-immunology-project-improve-disease
  2. https://www.crunchbase.com/organization/owlstone-medical-2#section-overview
  3. http://www.3tr-imi.eu

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.